Recent Finacing
Recent Raise
Draupnir Bio develops oral small-molecule lysosome-based degraders that target extracellular and traditionally hard-to-drug proteins, advancing a diversified preclinical pipeline from Copenhagen, spun out of Aarhus University and Max‑Planck
